Medical Assessments: Vaccine Damage Payment Scheme

Tender description

Contract for the provision of medical assessments in relation to the Vaccine Damage Payment Scheme (VDPS). Further information on the scheme can be found here https://www.gov.uk/vaccine-damage-payment/eligibility<br/><br/>VDPS eases the present and future burdens of those suffering from vaccine damage and provides assistance to their families. The assessment determines the causation and disablement as a result of vaccinations against specified diseases as set out in the VDPS. Lot 1: The services required are for Medical Assessments of the evidence being presented by applicants making a claim under the VDPS. An ‘Assessment’ is the end-to-end process to assess causation and level of disablement against the medical evidence presented in relation to a Claimant’s health condition and/or disability.<br/><br/>The Supplier is required to undertake all appropriate action to complete the assessment. This may include gathering evidence from the most appropriate source/reference/expert/specialist to ensure a definitive view can be provided.<br/><br/>Historically, the average number of annual assessments is c100 however volumes have increased following the addition of Covid and Adult Flu vaccinations to the VDPS. There is no minimum (or maximum) commitment to the number of assessments that will be required under the contract as the scheme is demand driven. It is estimated that in year one of the contract there will be c1500-1800 claims that will require assessment within the first year of the contract. It is estimated that after year 1 of the contract the number of assessments will between 100-1000 assessments will be required per annum. Additional information: The estimated value set out in the Contract Notice (2021/S 000-028514) was 6000000GBP ex VAT. As per the Contract Notice, this estimate could be affected by the variable volume of assessments required over the term of the Contract and the value could therefore be more or less that the amount stated in section II.1.7.